A Phase I/II Study of MEDI4736 in Combination with Olaparib in Patients with Advanced Solid Tumors. - MEDIOLA

Study identifier:D081KC00001

ClinicalTrials.gov identifier:NCT02734004

EudraCT identifier:2015-004005-16

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors

Medical condition

ovarian

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Olaparib, MEDI4736, Bevacizumab

Sex

All

Actual Enrollment

264

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 17 Mar 2016
Primary Completion Date: 17 Sept 2021
Estimated Study Completion Date: 17 Sept 2025

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

IQVIA (formerly QuintilesIMS)

Inclusion and exclusion criteria